Medline ® Abstract for Reference 14
of 'Immunotherapy of non-small cell lung cancer with immune checkpoint inhibition'
Rizvi NA, Brahmer JR, Ou S-HI, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 33(S1):8032.
no abstract available